Articles tagged with Edema
A new study shows Pycnogenol, a natural plant extract from pine bark, reduces jetlag symptoms by nearly 50% in both healthy individuals and hypertensive patients. The study found significant reductions in fatigue, headaches, insomnia, and brain edema, as well as minimal lower leg edema.
A study by NIAID scientist Theodore E. Nash found a strong association between brain tissue swelling and seizures in people infected with the parasitic tapeworm Taenia solium. Perilesional edema, a type of swelling around dead cysts, was seen in 50% of patients with seizures, suggesting a novel mechanism behind the condition.
The READ-2 study, a collaboration between JDRF, Johns Hopkins, and Genentech, found that ranibizumab injections significantly improved visual acuity and reduced excess retinal thickness in patients with diabetic macular edema. The treatment resulted in a 56% reduction in retinal thickness compared to laser photocoagulation therapy.
A Phase 2 clinical trial for ranibizumab is enrolling patients with diabetic macular edema to assess its long-term safety and effectiveness. The trial aims to investigate the use of ranibizumab in combination with laser photocoagulation for treating DME.
A study published in Clinical and Applied Thrombosis/Hemostasis reveals Pycnogenol, an antioxidant plant extract from pine tree bark, effectively reduces swelling in patients taking antihypertensive medications by 36%. The treatment also improves blood circulation, avoiding blood pooling and reducing edema.
Researchers at Yale University found that Ang2 protein levels are higher in patients with acute lung injury and pulmonary edema. The study suggests that modulating Ang2 levels may help control acute lung injury, offering new potential therapeutic targets.
Researchers found Pycnogenol to be more effective than Daflon in reducing leg swelling, walking pain, and skin alterations. The study showed a significant reduction in ankle swellings and edema scores with Pycnogenol supplementation.
Researchers have identified a molecular mechanism controlling lung dryness and fluid entry, potentially leading to better prognosis for those with acute respiratory distress syndrome. The discovery focuses on the SIP3 receptor, which, when activated, causes pulmonary edema, offering new avenues for treatment.
Researchers found that TZD activates PPAR-gamma in the kidney's collecting duct, leading to fluid retention and edema. The study opens new avenues for treating Type II diabetes and hypertension.
Research found that children of mothers with preeclampsia have higher systolic pulmonary artery pressure, linked to re-entry altitude sickness and potential long-term health risks. The study suggests new ways to prevent and treat primary pulmonary hypertension.
A study found that radiologists can identify potential problems with MRI, allowing for early treatment and prevention of injuries. Orthotics were provided to two athletes, preventing surgery and enabling them to play the entire season.
Researchers discovered two small molecules that can block anthrax toxins, including edema factor and lethal factor. These compounds, Nitro10506-2A and DS-998, may lead to new treatments for the deadly disease, but further testing is needed.
A study published in Investigative Ophthalmology & Visual Science found that breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula, and improved visual acuity in some cases. The therapy was found to reduce excess thickness of the macula by an average of 43 percent.
Researchers at Scripps Research Institute have discovered a way to block fluid leakage that causes long-term tissue injury after a heart attack. A single dose of a compound can drastically reduce tissue injury and increase long-term survival following a heart attack.
Researchers have found that a clinically approved drug for chronic hepatitis B can block the action of an anthrax toxin. Adefovir dipivoxil effectively reduces the effects of edema factor, one of two deadly toxins produced by anthrax, at non-toxic doses.
The American Academy of Ophthalmology released its February 2004 journal, showcasing groundbreaking research in the field. The publication highlights significant breakthroughs in ophthalmic care and treatment options.
Researchers at UT Southwestern Medical Center report that pioglitazone and rosiglitazone can cause or exacerbate heart failure and pulmonary edema in certain patients, highlighting the need for cautious prescribing practices.
The study reveals the structure of edema factor, a toxin that causes fluid accumulation and disrupts immune function. The researchers found that calmodulin binds to edema factor, changing its shape and making it more potent, providing an ideal drug target for developing anti-anthrax drugs.
A common treatment for diabetic crisis in children may contribute to a rare but often-fatal complication known as cerebral edema. Two simple blood test measurements can help predict which patients are at greatest danger of developing the potentially deadly complication.